Day : Friday
Date: 4/27/2007

Time: 20:01:55

PALM INTRANET

Inventor Information for 10/622303

Inventor Name	City	State/Country
SUNG, HSING-WEN	HSINCHU	TAIWAN
LIANG, HUANG-CHIEN	HSINCHU	TAIWAN
CHANG, WEN-HSIANG	HSINCHU	TAIWAN
TU, HOSHENG	NEWPORT BEACH	CALIFORNIA

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign D

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"6624138".pn.	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 15:38
L2	1	"200289679"	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 15:40
L3	2	"20020089679"	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 15:39
L4	2	"2002089679"	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 15:38
L5	11	"1392182"	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/04/27 15:39
L6	0	tina adj patel	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 15:40
L7	19	patel and dieck	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:22
L8	18	genipin near (gelatin or collagen or chitosan)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:23
L9	16	l8 and heparin	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:40
L10	2	"6608040".pn.	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:46
L11	43011	biomedical	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:46
L12	5533	l11 and heparin	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:46
L13	1851	l12 and (collagen and gelatin)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:56
L14	451	l13 and (antithrombotic or anticoagulant)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:47

EAST Search History

L15	164	l14 and (stent)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:47
L16	904	l13 and (wound and graft)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 16:57
L17	264	l16 and stent	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 17:09
L18	43710	l17 nad restenosis	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 17:09
L19	171	l17 and restenosis	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 17:14
L20	1	l19 and (gp adj medical)	US-PGPUB; USPAT; DERWENT	OR	OFF	2007/04/27 17:15
L21	162	l19 and implant	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 17:19
L22	1	"9819718"	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 17:19
L23	2	"6545042".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:03
L24	45559	microsphere	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 17:43
L25	8390	l24 and collagen	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 17:44
L26	937	l25 and (cross adj link)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 17:44
L27	613	l26 and (stent or implant)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:47
L28	2	"6545097".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:03
L29	518	l27 and gelatin	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:47

EAST Search History

L30	0	l28 and (cross adj link?)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:47
L31	13828	l29and (cross adj link?)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:48
L32	368	l29 and (cross adj link?)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:57
L33	4104	l31 and (oral or intramuscular)	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 18:49
L34	269	l32 and diameter	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 19:17
L35	2	"5763579".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 19:36
L36	2	"6624138".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 19:45
L37	3	"710857".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 19:45
L38	2	"7101857".pn.	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/27 19:45

```
=> file genipin
'GENIPIN' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 19:29:52 ON 26 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 APR 2007  HIGHEST RN 932710-95-7
DICTIONARY FILE UPDATES:  25 APR 2007  HIGHEST RN 932710-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s genipin/cn
L1            1 GENIPIN/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   6902-77-8  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Cyclopenta[c]pyran-4-carboxylic acid, 1,4a,5,7a-tetrahydro-1-hydroxy-7-
     (hydroxymethyl)-, methyl ester, (1R,4aS,7aS)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Cyclopenta[c]pyran-4-carboxylic acid, 1,4a,5,7a-tetrahydro-1-hydroxy-7-
     (hydroxymethyl)-, methyl ester, [1R-(1α,4aα,7aα)]-
CN   Cyclopenta[c]pyran-4-carboxylic acid, 1,4aα,5,7aα-tetrahydro-1-
     hydroxy-7-(hydroxymethyl)-, methyl ester (8CI)
CN   Genipin (6CI)
OTHER NAMES:
CN   (+)-Genipin
FS   STEREOSEARCH
MF   C11 H14 O5
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD,
       CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CSCHEM, DDFU, DRUGU,
       EMBASE, IFICDB, IFIUDB, IPA, MEDLINE, NAPRALERT, PHAR, PROMT, PROUSDDR,
       RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

262 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
265 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.35	7.56

FILE 'CAPLUS' ENTERED AT 19:30:08 ON 26 APR 2007

FILE COVERS 1907 - 26 Apr 2007 VOL 146 ISS 18
FILE LAST UPDATED: 25 Apr 2007 (20070425/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1 <> or genipin?

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION

```
FULL ESTIMATED COST                                    0.47       8.03

FILE 'REGISTRY' ENTERED AT 19:30:16 ON 26 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1-
L2          SEL L1 1- CHEM :        3 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  11.65      19.68

FILE 'CAPLUS' ENTERED AT 19:30:17 ON 26 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

S L2 OR GENIPIN?


           330 GENIPIN?
L4         334 L3 OR GENIPIN?

=> s l4 and (collagen or gelatin)
         90822 COLLAGEN
         64048 COLLAGENS
        101162 COLLAGEN
                 (COLLAGEN OR COLLAGENS)
         70097 GELATIN
         28621 GELATINS
         80191 GELATIN
                 (GELATIN OR GELATINS)
L5          77 L4 AND (COLLAGEN OR GELATIN)

=> s l5 and (heparin or anticoagulants or enoxaparin or ?parin )
         49133 HEPARIN
          1912 HEPARINS
         49262 HEPARIN
                 (HEPARIN OR HEPARINS)
         23119 ANTICOAGULANTS
           934 ENOXAPARIN
         50725 ?PARIN
L6          16 L5 AND (HEPARIN OR ANTICOAGULANTS OR ENOXAPARIN OR ?PARIN )

=> focus
PROCESSING COMPLETED FOR L6
L7          16 FOCUS L6 1-

=> d ibib abs 1-16

L7   ANSWER 1 OF 16  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2005:497233  CAPLUS
DOCUMENT NUMBER:         143:32417
TITLE:                   Drug-eluting stent having collagen drug
                         carrier chemically treated with genipin
```

INVENTOR(S): Sung, Hsing-Wen; Chen, Mei-Chin; Tu, Peter Y.; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 717,162.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123582	A1	20050609	US 2004-811413	20040326
WO 9819718	A1	19980514	WO 1997-US20113	19971104
W: CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1260237	A1	20021127	EP 2002-19186	19971104
R: DE, FR, GB, IT				
US 6608040	B1	20030819	US 2001-297808	20010927
US 6624138	B1	20030923	US 2002-211656	20020802
US 2003191071	A1	20031009		
US 2005163818	A1	20050728	US 2003-610391	20030630
AU 2004289270	A1	20050526	AU 2004-289270	20041105
CA 2545136	A1	20050526	CA 2004-2545136	20041105
EP 1689322	A1	20060816	EP 2004-818654	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.:

US 1996-30701P	P	19961105
WO 1997-US20113	W	19971104
US 2001-297808	A2	20010927
US 2002-211656	A2	20020802
US 2003-610391	A2	20030630
US 2003-492874P	P	20030806
US 2003-518050P	P	20031107
US 2003-717162	A2	20031119
US 2004-547935P	P	20040226
US 2004-552517P	P	20040312
EP 1997-947356	A3	19971104
US 2002-393565P	P	20020702
US 2004-565438P	P	20040426
US 2004-574501P	P	20040526
US 2004-610391	A	20040630
US 2004-585775P	P	20040706
WO 2004-US37217	W	20041105

OTHER SOURCE(S): MARPAT 143:32417

AB A method for treating vulnerable plaques of a patient, comprising: providing a biodegradable stent comprising a first supporting zone made of a first biodegradable material, wherein the supporting zone comprises at least a portion of continuous circumference of the stent; and a second therapeutic zone made of a second biodegradable material, wherein the therapeutic zone comprises at least one bioactive agent; delivering the biodegradable stent to the vulnerable plaques; orienting the therapeutic zone at about the luminal surface of the vulnerable plaque; and releasing the at least one bioactive agent for treating the vulnerable plaques.

L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:749996 CAPLUS
DOCUMENT NUMBER: 139:265760
TITLE: Drug-loaded biological material treated with **genipin**
INVENTOR(S): Sung, Hsing-wen; Tu, Hosheng
PATENT ASSIGNEE(S): GP Medical, USA
SOURCE: U.S., 18 pp., Cont.-in-part of U. S. Ser. No. 297,808.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6624138	B1	20030923	US 2002-211656	20020802
US 2003191071	A1	20031009		
WO 9819718	A1	19980514	WO 1997-US20113	19971104
W: CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1260237	A1	20021127	EP 2002-19186	19971104
R: DE, FR, GB, IT				
US 6608040	B1	20030819	US 2001-297808	20010927
US 2005163818	A1	20050728	US 2003-610391	20030630
WO 2004012676	A2	20040212	WO 2003-US24445	20030801
WO 2004012676	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003257179	A1	20040223	AU 2003-257179	20030801
EP 1545505	A2	20050629	EP 2003-767189	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500975	T	20060112	JP 2004-526437	20030801
US 2005123582	A1	20050609	US 2004-811413	20040326
US 2005163821	A1	20050728	US 2005-906239	20050210

PRIORITY APPLN. INFO.:

US 1996-30701P	P	19961105
WO 1997-US20113	W	19971104
US 2001-297808	A2	20010927
US 2002-393565P	P	20020702
EP 1997-947356	A3	19971104
US 2002-211656	A2	20020802
US 2003-610391	A2	20030630
WO 2003-US24445	W	20030801
US 2003-492874P	P	20030806
US 2003-518050P	P	20031107
US 2003-717162	A2	20031119
US 2004-547935P	P	20040226
US 2004-552517P	P	20040312
US 2004-916170	A2	20040811
US 2004-24101	A2	20041228

AB A method for treating tissue of a patient comprises, in combination, mixing a drug with a solidifiable biol. material, chemical treating the drug with the biol. material with a crosslinking agent, loading the solidifiable drug-containing biol. material onto a medical device, solidifying the drug-containing biol. material; and delivering the medical device to a target tissue for treating the tissue. Taxol is dispersed in a **collagen** solution at 4°. The drug containing **collagen** is loaded onto a stent and subsequently raise the temperature to about 37° to solidify **collagen** fibers on the stent. The loading step may repeat a plurality of times. Subsequently, the coated stent is crosslinked with aqueous **genipin**.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:672608 CAPLUS
DOCUMENT NUMBER: 143:159586
TITLE: Drug-eluting device chemically treated with **genipin**
INVENTOR(S): Sung, Hsing-wen; Chen, Mei-chin; Liang, Hsiang-fa; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 211,656.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005163818	A1	20050728	US 2003-610391	20030630
WO 9819718	A1	19980514	WO 1997-US20113	19971104
W: CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1260237	A1	20021127	EP 2002-19186	19971104
R: DE, FR, GB, IT				
US 6608040	B1	20030819	US 2001-297808	20010927
US 6624138	B1	20030923	US 2002-211656	20020802
US 2003191071	A1	20031009		
US 2005123582	A1	20050609	US 2004-811413	20040326
US 2005019404	A1	20050127	US 2004-916170	20040811
WO 2005046519	A1	20050526	WO 2004-US37217	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD				
US 2005163821	A1	20050728	US 2005-906239	20050210

PRIORITY APPLN. INFO.:

US 1996-30701P	P	19961105
WO 1997-US20113	W	19971104
US 2001-297808	A2	20010927
US 2002-211656	A2	20020802
EP 1997-947356	A3	19971104
US 2002-393565P	P	20020702
US 2003-610391	A2	20030630
US 2003-492874P	P	20030806
US 2003-518050P	P	20031107
US 2003-717162	A2	20031119
US 2004-547935P	P	20040226
US 2004-552517P	P	20040312
US 2004-565438P	P	20040426
US 2004-574501P	P	20040526
US 2004-585775P	P	20040706
US 2004-916170	A2	20040811
US 2004-24101	A2	20041228

AB A method for treating a target tissue of a patient comprises, in combination, mixing a drug with a solid-forming biol. material, chemical treating the drug with the biol. material with a crosslinking agent, loading the drug-containing biol. material onto a medical device, solidifying the drug-containing biol. material; and delivering the medical device to the

target tissue for treating the tissue. Thus, a chitosan solution was adjusted to approx. pH 5.5, and a drug was added to the solution This was loaded onto a stent, and the device was treated with **genipin**.

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:796767 CAPLUS
DOCUMENT NUMBER: 145:218126
TITLE: Drug-eluting biodegradable polymer-containing stents for treating atherosclerosis
INVENTOR(S): Sung, Hsing-Wen; Chen, Mei-Chin; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 56pp., Cont.-in-part of U.S. Ser. No. 906,239.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006177480	A1	20060810	US 2005-130787	20050517
US 2005163821	A1	20050728	US 2005-906239	20050210
PRIORITY APPLN. INFO.:			US 2005-906239 A2	20050210
			US 2002-211656 A2	20020802
			US 2003-610391 A2	20030630
			US 2004-916170 A2	20040811
			US 2004-24101 A2	20041228

OTHER SOURCE(S): MARPAT 145:218126
AB The present invention relates to a drug-eluting stent for treating atherosclerosis made of a biodegradable material comprising a luminal surface portion with a second degree of crosslink, an outer surface portion with a first degree of crosslink, and a wall between the luminal and outer surface portions, wherein the wall comprises a crosslinked material, e.g., chitosan or **collagen**, characterized by the first degree of crosslink not less than the second degree of crosslink. The biodegradable stent material is selected from **collagen**, **gelatin**, elastin, chitosan, polylactic acid, polyglycolic acid, polycaprolactone, polyesters, polyphosphazenes, polyetheresters, polyesteramides, etc. The biodegradable material is crosslinked with a crosslinking agent, e.g., **genipin**, glutaraldehyde, formaldehyde, etc., or with UV or gamma irradiation Thus, paclitaxel was dispersed in a **collagen** solution at about 4° and the drug-containing **collagen** was then loaded onto a stent by raising the temperature to about 37° to solidify **collagen** fibers on the stent. The loading step might be repeated a plurality of times. Subsequently, crosslinking of the coated stent with aqueous **genipin** was carried out. The crosslinking on the drug carrier (**collagen**) substantially modified the drug diffusion or eluting rate depending on the degree of crosslinking.

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:30963 CAPLUS
DOCUMENT NUMBER: 136:241388
TITLE: Antithrombotic effect of geniposide and **genipin** in the mouse thrombosis model
AUTHOR(S): Suzuki, Yasuhiro; Kondo, Kazunao; Ikeda, Yasuhiko; Umemura, Kazuo
CORPORATE SOURCE: Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan
SOURCE: Planta Medica (2001), 67(9), 807-810
CODEN: PLMEAA; ISSN: 0032-0943
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Geniposide is one of the constituents of Gardenia fruit (Gardenia jasminoides Ellis, Rubiaceae), which has been used in traditional medicine. Although its anti-inflammatory and antithrombotic effects have been reported, the way it acts is still unclear. We have investigated the effects of geniposide and its metabolite **genipin** on thrombogenesis and platelet aggregation. In an in vivo model, geniposide and **genipin** significantly ($P < 0.05$) prolonged the time required for thrombotic occlusion induced by photochem. reaction in the mouse femoral artery. In an in vitro study, both geniposide and **genipin** inhibited **collagen**-induced, but did not inhibit arachidonate-induced, mouse platelet aggregation. However aspirin, a cyclooxygenase inhibitor, inhibited arachidonate-induced platelet aggregation but only partially inhibited the **collagen**-induced one. We also showed, by measuring PLA2-catalyzed arachidonic acid release, that geniposide inhibited phospholipase A2 (PLA2) activity. We conclude that geniposide showed an antithrombotic effect in vivo due to the suppression of platelet aggregation. PLA2 inhibition by geniposide is one possible anti-platelet mechanism.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1101255 CAPLUS

DOCUMENT NUMBER: 144:74690

TITLE: Cell-free xenogenic vascular grafts fixed with glutaraldehyde or **genipin**: In vitro and in vivo studies

AUTHOR(S): Chang, Yen; Hsu, Cheng-Kuo; Wei, Hao-Ji; Chen, Sung-Ching; Liang, Huang-Chien; Lai, Po-Hong; Sung, Hsing-Wen

CORPORATE SOURCE: Division of Cardiovascular Surgery, Veterans General Hospital-Taichung and College of Medicine, National Yang-Ming University, Taipei, Taichung, Taiwan

SOURCE: Journal of Biotechnology (2005), 120(2), 207-219
CODEN: JBITD4; ISSN: 0168-1656

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Chronic rejection of arterial xenografts results in aneurysmal dilation, due to immune mediated processes. To minimize the immunol. degradation of the graft, a cell-extraction process employing sodium dodecyl sulfate (SDS) was used in the study to remove the cellular components in bovine carotid arteries. To further reduce their immunogenicity, the acellular arteries were fixed with glutaraldehyde (A-GA) or **genipin** (A-GP). The in vitro properties of all test samples were analyzed. Addnl., the in vivo performance of the heparinized A-GA and A-GP grafts (H-A-GA and H-A-GP) was evaluated in a canine model. It was found that the SDS treatment effectively removed cells from the arterial wall, but the main structures of the extracellular matrix were preserved with a portion of the water-soluble glycosaminoglycans removed. After cell extraction, the elastic lamellae in the media became straightened, and thus made the tissue less extensile. The heparinized tissues significantly reduced platelet adhesion. At retrieval, all implanted grafts were patent and not dilated. Chronic inflammatory response surrounding the implants was observed However, fixation of acellular tissues by glutaraldehyde or **genipin** inhibited immune cell penetration into the media and limited tissue degradation, and therefore prevented the arterial wall from dilation. Nevertheless, the H-A-GP graft was superior to the H-A-GA graft in completeness of endothelialization on its luminal surface, and thus precluded thrombus formation.

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7. ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:148238 CAPLUS
DOCUMENT NUMBER: 144:239929
TITLE: Drug eluting stents made from crosslinked biodegradable materials and drugs
INVENTOR(S): Sung, Hsing-Wen; Liang, Hsiang-Fa; Huang, Chin-Tsung; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 916,170.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006034885	A1	20060216	US 2004-929047		20040827
US 2005019404	A1	20050127	US 2004-916170		20040811
PRIORITY APPLN. INFO.:			US 2004-916170	A2	20040811
			US 2003-610391	A2	20030630
			US 2003-518050P	P	20031107
			US 2004-547935P	P	20040226
			US 2004-565438P	P	20040426
			US 2004-574501P	P	20040526
			US 2004-585775P	P	20040706

OTHER SOURCE(S): MARPAT 144:239929
AB The present invention relates to a drug-loaded biodegradable stent and methods for treating vulnerable plaques of a patient comprising a plurality of layers or zones, each layer or zone comprising its own specific biodegrdn. rate and its specific drug loading characteristics. In one embodiment, the layers and zones are configured and arranged, in combination, radially, circumferentially and longitudinally. For example, a stent made from **genipin**-crosslinked chitosan was loaded with Taxol for controlled release of the antitumor agent.

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:619958 CAPLUS
DOCUMENT NUMBER: 145:278390
TITLE: Biocompatible sponges entrapping growth factors for the promotion of skin repair and its production method
INVENTOR(S): Huang, Zhifeng; Li, Xiaokun; Ding, Shan; Zheng, Qing; Xu, Hua; Tan, Yi; Pan, Jianchun
PATENT ASSIGNEE(S): Wenzhou Medical College, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 14 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1788802	A	20060621	CN 2005-10022581	20051214
PRIORITY APPLN. INFO.:			CN 2005-10022581	20051214

AB The title sponges are made from modified **collagen** (such as chitosan or glycosaminoglycan), wherein the material also entrap one or more growth factors (in an amount ≥10 ng) selected from fibroblast growth factor, epidermal growth factor, nerve growth factor and connective tissue growth factor. The production method comprises extracting **collagen** from animal skin, cartilage and tendon, and dissolving the **collagen** to form a **collagen** solution; dissolving chitosan or glycosaminoglycan in water to form a solution; and mixing the above

solns., standing for a while to allow crosslinking reaction, adding solution of a growth factor under stirring tenderly, freeze-drying the mixture, and wrapping in sterile package. The sponges can release growth factor sustainedly around the wound so as to promote wound healing and new tissue regeneration. The bioactive sponge material can be used for hemostasis in surgery or wound treatment, and also for the repair of wound due to burn and scald, tissue defect, ulcer (including decubital ulcer), fistulous tract, and cervical erosion.

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:497471 CAPLUS
DOCUMENT NUMBER: 143:32422
TITLE: Crosslinkable biological material and angiogenic agent for promoting angiogenesis
INVENTOR(S): Sung, Hsing-Wen; Liang, Huang-Chien; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 408,176.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005124560	A1	20050609	US 2004-827673	20040419
US 7101857	B2	20060905		
WO 9819718	A1	19980514	WO 1997-US20113	19971104
W: CA, CN, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1260237	A1	20021127	EP 2002-19186	19971104
R: DE, FR, GB, IT				
US 6608040	B1	20030819	US 2001-297808	20010927
US 2002091445	A1	20020711	US 2002-67130	20020204
US 6545042	B2	20030408		
US 6998418	B1	20060214	US 2003-408176	20030407
AU 2004289270	A1	20050526	AU 2004-289270	20041105
CA 2545136	A1	20050526	CA 2004-2545136	20041105
EP 1689322	A1	20060816	EP 2004-818654	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.:

US 1996-30701P	P	19961105
WO 1997-US20113	W	19971104
US 2001-297808	A2	20010927
US 2002-67130	A2	20020204
US 2003-408176	A2	20030407
US 2003-492874P	P	20030806
US 2003-518050P	P	20031107
US 2003-526434P	P	20031202
US 2004-547935P	P	20040226
US 2004-552517P	P	20040312
EP 1997-947356	A3	19971104
US 2004-565438P	P	20040426
US 2004-574501P	P	20040526
US 2004-610391	A	20040630
US 2004-585775P	P	20040706
WO 2004-US37217	W	20041105

AB A method for promoting angiogenesis in a patient comprising providing crosslinkable biol. solution to the target tissue, wherein the crosslinkable biol. solution is loaded with at least one angiogenic agent. In one embodiment, the at least one angiogenic agent is a non-protein factor selected from a group consisting of ginsenoside Rg1, ginsenoside Re, combination thereof and the like. In another embodiment, the

crosslinkable biol. solution of the present invention is broadly defined in a form or phase of solution, paste, gel, suspension, colloid or plasma that may be solidifiable thereafter. For example, to increase pore sizes and porosities within test samples, the acellular pericardia were treated with acetic acid and collagenase. Subsequently, acellular tissues were fixed in a 0.05% **genipin** at 37° for 3 days. **Genipin**, as a crosslinking agent, was significantly less cytotoxic compared to glutaraldehyde used as a control.

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:497234 CAPLUS
DOCUMENT NUMBER: 143:32418
TITLE: Medical use of reuterin
INVENTOR(S): Sung, Hsing-Wen; Chen, Chun-Nan; Liang, Hsiang-Fa; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 282,852.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123583	A1	20050609	US 2004-924538	20040824
US 2002122816	A1	20020905	US 2000-737482	20001218
PRIORITY APPLN. INFO.:			US 2000-737482	A2 20001218
			US 2002-282852	A2 20021029

AB Use of reuterin, a naturally occurring β-hydroxypropinoaldehyde, in the manufacture of a biocompatible implant is disclosed, which involves crosslinking an amine-containing biol. material such as chitosan, **collagen**, elastin, **gelatin**, fibrin glue, and combination thereof with reuterin.

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:868787 CAPLUS
DOCUMENT NUMBER: 137:358231
TITLE: Coated combination vaso-occlusive device
INVENTOR(S): Ken, Christopher G. M.; Patel, Tina J.
PATENT ASSIGNEE(S): Concentric Medical, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089865	A2	20021114	WO 2002-US14169	20020506
WO 2002089865	A3	20030220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002340749	A1	20021118	AU 2002-340749	20020506
PRIORITY APPLN. INFO.:			US 2001-288467P	P 20010504

WO 2002-US14169 W 20020506

AB Methods, compns. and apparatus are disclosed for treating abnormal conditions within a body. The apparatus includes vaso-occlusion devices each comprising a core formed of a metal, metal alloy, or non-metal material. Each core is coated with a polymer material that can include a bioactive agent. The methods include treating patients having abnormal blood flow at a site in their body by implanting such a coated vaso-occlusive device into the body at the site of the abnormal blood flow. The methods also include a method of making the vaso-occlusion devices. The compns. include coatings for the vaso-occlusive devices.

L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:697009 CAPLUS
DOCUMENT NUMBER: 145:218071
TITLE: Method for preparing blood-compatible biomaterial
INVENTOR(S): Yan, Yongnian; Wang, Xiaohong; Lin, Feng; Xiong, Zhuo; Wu, Rendong; Zhang, Renji
PATENT ASSIGNEE(S): Tsinghua University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 12 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1799649	A	20060712	CN 2005-10126364	20051209
PRIORITY APPLN. INFO.:			CN 2005-10126364	20051209

AB The title method comprises: mixing a medical polymer with an anticoagulant, adding pore-forming agent or filler, and making thin-film, fiber, hollow fiber, non-woven fabric, tube, or mesh by coating, dribbling, electrocoating, spinning, rapid forming, or electro-spinning method. In the biomaterial, the anticoagulant accounts for 0.001-10% by mass of the medical polymer, and the pore-forming agent or filler accounts for 0-20% by mass of the medical polymer. The biomaterial can be used for anticoagulant treatment in vitro or used as implant for tissue repair, and has the advantages of long-acting anticoagulant effect, good bioavailability, and high mech. strength and flexibility.

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:633901 CAPLUS
DOCUMENT NUMBER: 145:90161
TITLE: An implantable biomaterial and a method of producing same
INVENTOR(S): Neethling, William Morris Leonard; Hodge, Andrew Julian
PATENT ASSIGNEE(S): Celxcel Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006066327	A1	20060629	WO 2005-AU1928	20051220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006193885 A1 20060831 US 2005-316584 20051221
PRIORITY APPLN. INFO.: AU 2004-907348 A 20041224

AB The present invention relates to an implantable biomaterial and methods of producing same. In particular, the present invention relates to a method for producing an implantable biomaterial comprising (a) exposing a biomaterial to an alc.-containing solution for at least 24 h.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:77978 CAPLUS
DOCUMENT NUMBER: 142:162660
TITLE: Biodegradable stent with crosslinked bioactive agent for slow release
INVENTOR(S): Sung, Hsing-Wen; Chen, Mei-Chin; Tu, Peter Y.; Tu, Hosheng
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 610,391.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005019404	A1	20050127	US 2004-916170	20040811
US 2005163818	A1	20050728	US 2003-610391	20030630
US 2006034885	A1	20060216	US 2004-929047	20040827
AU 2004289270	A1	20050526	AU 2004-289270	20041105
CA 2545136	A1	20050526	CA 2004-2545136	20041105
EP 1689322	A1	20060816	EP 2004-818654	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 2005163821	A1	20050728	US 2005-906239	20050210
WO 2006033686	A1	20060330	WO 2005-US19930	20050608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

US 2003-610391	A2	20030630
US 2003-518050P	P	20031107
US 2004-547935P	P	20040226
US 2004-565438P	P	20040426
US 2004-574501P	P	20040526
US 2004-585775P	P	20040706
US 1996-30701P	P	19961105
WO 1997-US20113	W	19971104
US 2001-297808	A2	20010927

US 2002-211656	A2	20020802
US 2004-610391	A	20040630
US 2004-916170	A2	20040811
WO 2004-US37217	W	20041105
US 2004-24101	A2	20041228

OTHER SOURCE(S): MARPAT 142:162660

AB The present invention relates to a drug-loaded biodegradable stent or implant for drug slow release and methods for treating vulnerable plaques of a patient comprising a plurality of layers or zones, each layer or zone comprising its own specific biodegrdn. rate and its specific drug loading characteristics. Specifically, the layers and zones are configured and arranged, in combination, radially, circumferentially and longitudinally. The crosslinked biodegradable stent or implant comprises at least one layer or zone of biol. material, said biol. material comprising at least one bioactive agent and being crosslinked with a means for crosslinking said biol. material.

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:868676 CAPLUS
DOCUMENT NUMBER: 137:358228
TITLE: Polymer-based hydrogel vaso-occlusive device
INVENTOR(S): Patel, Tina J.; Ken, Christopher G. M.; Dieck, Martin S.
PATENT ASSIGNEE(S): Concentric Medical, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

US2002/0193812

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089679	A1	20021114	WO 2002-US13870	20020506
WO 2002089679	A9	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002340645	A1	20021118	AU 2002-340645	20020506
EP 1392182	A1	20040303	EP 2002-769309	20020506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

US 2001-288494P	P	20010504
WO 2002-US13870	W	20020506

AB Methods and apparatus useful in performing vaso-occlusion at a site of abnormal blood flow in the body are described. A vaso-occlusive device for implantation into the vasculature of a patient comprises at least one polymer capable of taking a form that can pass through a delivery device to a site of abnormal blood flow whereupon it assumes a vaso-occluding shape at the site. The form that can pass through the delivery device is selected from a solid, such as a strip, rod, sheet, roll, etc., or a liquid The device further comprises a bioactive agent, selected from a growth factor, an endothelization factor, a cell or tissue adhesion factor, a healing factor, an immunol. factor, a tumor suppressor, etc. The vaso-occlusive device can be applied to treatment for aneurysms, arterio-venous malformation (AVMs), fistulas, ruptured blood vessels and benign or malignant tumors.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:961474 CAPLUS
DOCUMENT NUMBER: 143:253990
TITLE: Anti-infectious hydrogel compositions
INVENTOR(S): Gruening, Rainer; Perschbacher, Doug J.; Qu, Xin; Buongiovanni, David
PATENT ASSIGNEE(S): Hydromer, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005191270	A1	20050901	US 2004-788663	20040227
AU 2005220708	A1	20050922	AU 2005-220708	20050218
CA 2555250	A1	20050922	CA 2005-2555250	20050218
WO 2005086641	A2	20050922	WO 2005-US5323	20050218
WO 2005086641	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006198814	A1	20060907	US 2006-416060	20060502

PRIORITY APPLN. INFO.: US 2004-788663 A 20040227
WO 2005-US5323 W 20050218

AB The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water.